title: Comparative evaluation of live marker vaccine candidates "CP7_E2alf" and "flc11" along with C-strain "Riems" after oral vaccination.
abstract: Due to the tremendous socio-economic impact of classical swine fever (CSF) outbreaks, emergency vaccination scenarios are continuously under discussion. Unfortunately, all currently available vaccines show restrictions either in terms of marker capacities or immunogenicity. Recent research efforts were therefore directed at the design of new modified live marker vaccines. Among the most promising candidates the chimeric pestiviruses "CP7_E2alf" and "flc11" were identified. Within an international research project, these candidates were comparatively tested in challenge experiments after a single oral vaccination. Challenge infection was carried out with highly virulent CSF virus strain "Koslov", 14 or 21 days post vaccination (dpv), respectively. Safety, efficacy, and marker potential were addressed. All assessments were done in comparison with the conventional "gold standard" C-strain "Riems" vaccine. In addition to the challenge trials, multiple vaccinations with both candidates were performed to further assess their marker vaccine potential. All vaccines were safe and yielded full protection upon challenge 21 days post vaccination. Neither serological nor virological investigations showed major differences among the three vaccines. Whereas CP7_E2alf also provided clinical protection upon challenge at 14 days post vaccination, only 50% of animals vaccinated with flc11, and 83% vaccinated with C-strain "Riems" survived challenge at this time point. No marked differences were seen in protected animals. Despite the fact that all multiple-vaccinated animals stayed sero-negative in the accompanying marker test, the discriminatory assay remains a weak point due to delayed or inexistent detection of some of the vaccinated and subsequently infected animals. Nevertheless, the potential as live marker vaccines could be confirmed for both vaccine candidates. Future efforts will therefore be directed at the licensing of "Cp7_E2alf" as the first live marker vaccine for CSF.
authors.affiliation: Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Suedufer 10, 17493 Greifswald - Insel Riems, Germany.
authors.forename: Sandra
authors.initials: S
authors.lastname: Blome
authors.forename: Andrea
authors.initials: A
authors.lastname: Aebischer
authors.forename: Elke
authors.initials: E
authors.lastname: Lange
authors.forename: Martin
authors.initials: M
authors.lastname: Hofmann
authors.forename: Immanuel
authors.initials: I
authors.lastname: Leifer
authors.forename: Willie
authors.initials: W
authors.lastname: Loeffen
authors.forename: Frank
authors.initials: F
authors.lastname: Koenen
authors.forename: Martin
authors.initials: M
authors.lastname: Beer
mesh_terms: D000818:Animals; D006691:Classical Swine Fever / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D006692:Classical Swine Fever Virus; D013047:Specific Pathogen-Free Organisms; D013552:Swine; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology; D022581:Vaccines, Marker / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects* / Q000276:immunology*
chemical_list: D014613:Vaccines, Attenuated; D022581:Vaccines, Marker; D014765:Viral Vaccines